Compare Cincinnati Financial Corporation (CINF) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cincinnati Financial Corporation vs Incyte Corporation — how do they compare? Cincinnati Financial Corporation trades at $175.97 (market cap $27.85B), while Incyte Corporation trades at $114.07 (market cap $22.95B). The key difference: Cincinnati Financial Corporation is the larger of the two by market cap, and Cincinnati Financial Corporation pays a 2.09% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| CINF | INCY | |
|---|---|---|
Market Cap | $27.85B | $22.95B |
Sector | Financials | Health |
52-Week High | $192.03 | $118.52 |
52-Week Low | $145.80 | $67.38 |
Enterprise Value | $27.52B | $18.97B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cincinnati Financial (CINF) trades at $182.67, up 1.89% with strong technical momentum near recent highs. The stock shows solid fundamentals with a P/E of 10.44, ROE of 18.73%, and consistent earnings beats in recent quarters. Recent news highlights the company's 65-year dividend streak and upcoming Q2 2026 earnings release on July 27, 2026. Operating cash flow improved to $3.11B in 2025, supporting financial stability.
CINF presents a balanced investment case with attractive valuation metrics and strong profitability, though catastrophe losses and claims costs remain key risks. Analyst consensus suggests moderate upside to the $188.67 price target. The stock's technical positioning near resistance at $184 requires monitoring of earnings performance for continued momentum.
Incyte (INCY) trades at $114.23, down 2.12% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.81, and revenue growth continues with 2025 revenue at $5.14 billion. Recent developments include positive Phase 1/2 data for VGA039 and the acquisition of Vega Therapeutics, expanding its hematology portfolio.
Outlook remains positive with analyst consensus favoring a Buy rating and a $112.78 price target. Key opportunities include pipeline advancements and robust profitability margins, while risks involve regulatory hurdles and competitive pressures in the biopharmaceutical sector. Earnings growth and product approvals are critical catalysts for future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
